EE417 Development and Application of a New Cost-Utility Model to Assess the Cost-Effectiveness of Palivizumab for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Moderate-to-Late Preterm Infants
Abstract
Authors
X. Carbonell-Estrany J Fullarton I Keary B Rodgers-Gray JE Tarride B Paes